Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

EMPIRIC THERAPY WITH AMPHOTERICIN-B IN FEBRILE GRANULOCYTOPENIC PATIENTS REVIEWS OF INFECTIOUS DISEASES Walsh, T. J., Lee, J., LECCIONES, J., Rubin, M., Butler, K., Francis, P., Weinberger, M., Roilides, E., Marshall, D., Gress, J., Pizzo, P. A. 1991; 13 (3): 496-503

Abstract

The early diagnosis of invasive fungal infection in granulocytopenic patients remains unreliable. Granulocytopenic patients who are persistently or recurrently febrile despite therapy with appropriate antibacterial agents are at high risk for the development of such infection. Two randomized clinical trials demonstrated that the empiric administration of amphotericin B to persistently or recurrently febrile granulocytopenic patients decreased the frequency, morbidity, and mortality of invasive fungal infection; these effects were especially marked in profoundly granulocytopenic patients who were not receiving antifungal prophylaxis. Current studies continue to indicate that prompt empiric administration of amphotericin B to persistently or recurrently febrile granulocytopenic patients ensures earlier treatment of deep mycoses. The roles of newer antifungal triazole compounds and of liposomal and lipid complexes of amphotericin B in empiric antifungal therapy must be investigated further in thoughtfully designed, randomized clinical trials.

View details for Web of Science ID A1991FM82600023

View details for PubMedID 1866556